Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
about
Strategic approaches to optimizing peptide ADME propertiesAn apparent clinical pharmacokinetic drug-drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism.Pharmacokinetics of teduglutide in subjects with renal impairment.FSTL3 is increased in renal dysfunction.
P2860
Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacokinetic predictions fo ...... on peptides and protein drugs.
@en
Pharmacokinetic predictions fo ...... on peptides and protein drugs.
@nl
type
label
Pharmacokinetic predictions fo ...... on peptides and protein drugs.
@en
Pharmacokinetic predictions fo ...... on peptides and protein drugs.
@nl
prefLabel
Pharmacokinetic predictions fo ...... on peptides and protein drugs.
@en
Pharmacokinetic predictions fo ...... on peptides and protein drugs.
@nl
P2093
P2860
P1476
Pharmacokinetic predictions fo ...... on peptides and protein drugs.
@en
P2093
David Czock
Frieder Keller
Hanna M Seidling
P2860
P356
10.1111/J.1365-2125.2012.04172.X
P407
P577
2012-07-01T00:00:00Z